fenofibrate has been researched along with Diabetic Glomerulosclerosis in 37 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia." | 9.34 | Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. ( Liu, J; Sun, X; Wang, G, 2020) |
| "Improvement in lipid profiles with fenofibrate in patients with type 2 diabetes was associated with reduced progression from normal albumin excretion to microalbuminuria." | 9.11 | Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Foucher, C; Rattier, S; Steiner, G; Taskinen, MR, 2005) |
| " In the present study, we sought to investigate in greater detail the effect of fenofibrate and its mechanism of action on renal inflammation and tubulointerstitial fibrosis in an animal model of type 2 diabetes mellitus." | 7.76 | Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. ( Emmett, N; Li, L; Mann, D; Zhao, X, 2010) |
| "This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia." | 5.34 | Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. ( Liu, J; Sun, X; Wang, G, 2020) |
| "In people with type 2 diabetes at high risk for cardiovascular disease, intensive glycemic control may result in a long-term reduction in macroalbuminuria; however, intensive BP control and fenofibrates may increase the risk for adverse kidney events." | 5.27 | Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. ( Buse, JB; Craven, TE; Ismail-Beigi, F; Katz, L; Mottl, AK; Mychaleckyj, JC; Papademetriou, V; Pedley, CF; Sigal, RJ; Simmons, DL, 2018) |
| "Improvement in lipid profiles with fenofibrate in patients with type 2 diabetes was associated with reduced progression from normal albumin excretion to microalbuminuria." | 5.11 | Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Foucher, C; Rattier, S; Steiner, G; Taskinen, MR, 2005) |
| " Fenofibrate significantly slowed the progression of early diabetic retinopathy by 30 to 40% within 4 to 5 years in patients with type 2 diabetes mellitus and pre-existing retinopathy at baseline." | 4.93 | Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review. ( Czupryniak, L; Gogtay, JA; Joshi, SR; Lopez, M, 2016) |
| " In the present study, we sought to investigate in greater detail the effect of fenofibrate and its mechanism of action on renal inflammation and tubulointerstitial fibrosis in an animal model of type 2 diabetes mellitus." | 3.76 | Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. ( Emmett, N; Li, L; Mann, D; Zhao, X, 2010) |
| "Diabetic nephropathy is associated with glomerular hypertrophy, glomerulosclerosis, tubulointerstitial fibrosis, mesangial cell expansion, followed by albuminuria and reduction in glomerular filtration rate." | 2.48 | Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney? ( Balakumar, P; Kadian, S; Mahadevan, N, 2012) |
| "Especially diabetic nephropathy is a leading cause of morbidity and mortality, and its prevalence is increasing." | 2.48 | Fibrates: therapeutic potential for diabetic nephropathy? ( Kouroumichakis, I; Liakopoulos, V; Maltezos, E; Mikhailidis, DP; Papanas, N; Zarogoulidis, P, 2012) |
| "Microalbuminuria is an early marker of diabetic nephropathy and an independent risk factor for cardiovascular disease." | 2.44 | Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection. ( Brown, WV, 2008) |
| "The attenuation of diabetic kidney disease (DKD) by metabolic surgery is enhanced by pharmacotherapy promoting renal fatty acid oxidation (FAO)." | 1.72 | Dietary restriction and medical therapy drives PPARα-regulated improvements in early diabetic kidney disease in male rats. ( Abdelaal, M; Abrahamsson, S; Brennan, EP; Chuah, YHD; Docherty, NG; Eckhardt, H; Elliott, JA; Fändriks, L; Fearon, N; Godson, C; Hutter, M; le Roux, CW; Malmodin, D; Martin, WP; Nair, M; Pedersen, A, 2022) |
| "Treatment with fenofibrate improved renal function by improving creatinine clearance (P = 0." | 1.48 | Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy. ( Mohammadi, MT; Rezaee, R; Sahebkar, A; Yaribeygi, H, 2018) |
| "Fenofibrate was administered 4 wk after the initiation of the HFD when renal injury was initiated." | 1.46 | Delayed treatment with fenofibrate protects against high-fat diet-induced kidney injury in mice: the possible role of AMPK autophagy. ( Ha, H; Hwang, I; Kang, H; Kim, H; Kim, K; Lee, G; Lee, JH; Sohn, M; Uddin, MJ, 2017) |
| "After 12 weeks, diabetic nephropathy biomarkers were assessed." | 1.43 | Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-β1/Smad3 signaling pathway. ( Al-Ajmi, HN; Al-Amin, MA; Al-Rasheed, NM; Attia, HA; Hasan, IH; Mohammad, RA, 2016) |
| "Treatment with fenofibrate significantly improved the renal function as revealed by the significant reductions in urinary albumin excretion and serum levels of creatinine and urea, in addition to the significant increase in creatinine clearance compared with the diabetic control group." | 1.42 | Renoprotective Effects of Fenofibrate via Modulation of LKB1/AMPK mRNA Expression and Endothelial Dysfunction in a Rat Model of Diabetic Nephropathy. ( Al-Ajmi, HN; Al-Amin, MA; Al-Rasheed, NM; Attia, HA; Hasan, IH; Mohamad, RA; Sinjilawi, NA, 2015) |
| "The development of diabetic nephropathy was assessed biochemically and histologically." | 1.39 | Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy. ( Balakumar, P; Kadian, S; Mahadevan, N, 2013) |
| "Treatment with fenofibrate (80 mg/kg/day, p." | 1.38 | The combined strategy with PPARα agonism and AT₁ receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat. ( Balakumar, P; Bishnoi, HK; Mahadevan, N, 2012) |
| "The development of diabetic nephropathy was assessed biochemically and histologically." | 1.36 | The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. ( Arora, MK; Balakumar, P; Reddy, K, 2010) |
| "Treatment with fenofibrate normalizes the altered lipid profile in diabetic rats, whereas benfotiamine treatment has no effect on lipid alteration in diabetic rats." | 1.35 | Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. ( Balakumar, P; Chakkarwar, VA; Singh, M, 2009) |
| "Treatment with fenofibrate or metformin ameliorated renal damage in OLETF rats through SREBP-1 and some enzyme regulated by it reduced fat deposit in kidney directly." | 1.33 | [Effect of fenofibrate and metformin on lipotoxicity in OLETF rat kidney]. ( Guo, XH; Wang, NH; Wang, W; Wu, HH; Xu, XS, 2006) |
| "Treatment with fenofibrate suppressed the expression of PAI-I mRNA and its protein activity, and inhibited TGF-beta1 overexpression." | 1.33 | Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1. ( Chen, LL; Wang, BP; Zhang, JY, 2006) |
| "Fenofibrate treatment dramatically reduced fasting blood glucose (P<0." | 1.33 | PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. ( Breyer, M; Cha, DR; Chen, L; Davis, L; Fan, X; Guan, Y; Hwang, MT; Park, CW; Striker, G; Su, D; Wu, J; Zhang, X; Zhang, Y; Zheng, F, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (32.43) | 29.6817 |
| 2010's | 21 (56.76) | 24.3611 |
| 2020's | 4 (10.81) | 2.80 |
| Authors | Studies |
|---|---|
| Martin, WP | 1 |
| Nair, M | 1 |
| Chuah, YHD | 1 |
| Malmodin, D | 1 |
| Pedersen, A | 1 |
| Abrahamsson, S | 1 |
| Hutter, M | 1 |
| Abdelaal, M | 1 |
| Elliott, JA | 1 |
| Fearon, N | 1 |
| Eckhardt, H | 1 |
| Godson, C | 1 |
| Brennan, EP | 1 |
| Fändriks, L | 1 |
| le Roux, CW | 1 |
| Docherty, NG | 1 |
| Tang, C | 1 |
| Deng, X | 1 |
| Qu, J | 1 |
| Miao, Y | 1 |
| Tian, L | 1 |
| Zhang, M | 1 |
| Li, X | 1 |
| Sun, B | 1 |
| Chen, L | 3 |
| Cheng, Y | 2 |
| Zhang, X | 2 |
| Ma, F | 1 |
| Sun, W | 2 |
| Wang, W | 2 |
| Yu, J | 1 |
| Shi, Y | 1 |
| Cai, L | 2 |
| Xu, Z | 2 |
| Sun, X | 1 |
| Liu, J | 1 |
| Wang, G | 2 |
| Yaribeygi, H | 1 |
| Mohammadi, MT | 1 |
| Rezaee, R | 1 |
| Sahebkar, A | 1 |
| Mottl, AK | 1 |
| Buse, JB | 1 |
| Ismail-Beigi, F | 1 |
| Sigal, RJ | 1 |
| Pedley, CF | 1 |
| Papademetriou, V | 1 |
| Simmons, DL | 1 |
| Katz, L | 1 |
| Mychaleckyj, JC | 1 |
| Craven, TE | 1 |
| Kim, Y | 2 |
| Hwang, SD | 1 |
| Lim, JH | 2 |
| Kim, MY | 2 |
| Kim, EN | 1 |
| Choi, BS | 2 |
| Kim, YS | 1 |
| Kim, HW | 4 |
| Park, CW | 4 |
| Kitajima, S | 1 |
| Furuichi, K | 1 |
| Wada, T | 1 |
| Zhao, X | 2 |
| Zhang, Y | 3 |
| Leander, M | 1 |
| Li, L | 2 |
| Emmett, N | 2 |
| Hong, YA | 1 |
| Kim, TW | 1 |
| Yang, KS | 1 |
| Park, HS | 1 |
| Choi, SR | 1 |
| Chung, S | 1 |
| Chang, YS | 2 |
| Balakumar, P | 6 |
| Varatharajan, R | 1 |
| Nyo, YH | 1 |
| Renushia, R | 1 |
| Raaginey, D | 1 |
| Oh, AN | 1 |
| Akhtar, SS | 1 |
| Rupeshkumar, M | 1 |
| Sundram, K | 1 |
| Dhanaraj, SA | 1 |
| Al-Rasheed, NM | 4 |
| Attia, HA | 2 |
| Al-Amin, MA | 2 |
| Al-Ajmi, HN | 2 |
| Hasan, IH | 2 |
| Mohamad, RA | 1 |
| Sinjilawi, NA | 1 |
| Zhang, J | 2 |
| Guo, W | 1 |
| Li, F | 1 |
| Chen, J | 1 |
| Zhang, C | 1 |
| Lu, X | 1 |
| Tan, Y | 1 |
| Feng, W | 1 |
| Fu, Y | 1 |
| Liu, GC | 1 |
| Mohammad, RA | 1 |
| Czupryniak, L | 1 |
| Joshi, SR | 1 |
| Gogtay, JA | 1 |
| Lopez, M | 1 |
| Sohn, M | 1 |
| Kim, K | 1 |
| Uddin, MJ | 1 |
| Lee, G | 1 |
| Hwang, I | 1 |
| Kang, H | 1 |
| Kim, H | 1 |
| Lee, JH | 1 |
| Ha, H | 1 |
| Cheng, R | 1 |
| Ding, L | 1 |
| He, X | 1 |
| Takahashi, Y | 1 |
| Ma, JX | 1 |
| Chakkarwar, VA | 1 |
| Singh, M | 1 |
| Brown, WV | 1 |
| Ansquer, JC | 2 |
| Foucher, C | 2 |
| Aubonnet, P | 1 |
| Le Malicot, K | 1 |
| Zimmet, P | 1 |
| Arora, MK | 1 |
| Reddy, K | 1 |
| Mann, D | 1 |
| Udani, SM | 1 |
| Bakris, GL | 1 |
| Kadian, S | 2 |
| Mahadevan, N | 3 |
| Lewis, D | 1 |
| Wanner, C | 1 |
| Kouroumichakis, I | 1 |
| Papanas, N | 1 |
| Zarogoulidis, P | 1 |
| Liakopoulos, V | 1 |
| Maltezos, E | 1 |
| Mikhailidis, DP | 1 |
| Bishnoi, HK | 1 |
| Yoshizawa, M | 1 |
| Takamura, T | 1 |
| Kobayashi, K | 1 |
| Rattier, S | 1 |
| Taskinen, MR | 1 |
| Steiner, G | 1 |
| Ko, SH | 1 |
| Chung, HW | 1 |
| Lim, SW | 1 |
| Yang, CW | 1 |
| Sugawara, A | 1 |
| Guan, Y | 2 |
| Breyer, MD | 1 |
| Guo, XH | 1 |
| Wu, HH | 1 |
| Wang, NH | 1 |
| Xu, XS | 1 |
| Chen, LL | 1 |
| Zhang, JY | 1 |
| Wang, BP | 1 |
| Varghese, Z | 1 |
| Moorhead, JF | 1 |
| Ruan, XZ | 1 |
| Wu, J | 1 |
| Cha, DR | 1 |
| Su, D | 1 |
| Hwang, MT | 1 |
| Fan, X | 1 |
| Davis, L | 1 |
| Striker, G | 1 |
| Zheng, F | 1 |
| Breyer, M | 1 |
| Wang, Y | 1 |
| Wang, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy[NCT02314533] | Phase 4 | 200 participants (Anticipated) | Interventional | 2014-12-31 | Not yet recruiting | ||
| Clinical Study to Evaluate the Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients[NCT06155331] | Phase 4 | 44 participants (Anticipated) | Interventional | 2023-12-31 | Recruiting | ||
| Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy[NCT03869931] | Phase 3 | 300 participants (Anticipated) | Interventional | 2019-03-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for fenofibrate and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
[Impact of dyslipidemia on the onset and progression of diabetic complications].
Topics: Cerebrovascular Disorders; Coronary Disease; Diabetic Angiopathies; Diabetic Nephropathies; Dyslipid | 2013 |
Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; Disease Progression; Drug C | 2016 |
Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dys | 2008 |
Fibrates and microvascular complications in diabetes--insight from the FIELD study.
Topics: Animals; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 2009 |
Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?
Topics: Animals; Diabetes Mellitus; Diabetic Nephropathies; Dyslipidemias; Fenofibrate; Humans; Hypolipidemi | 2012 |
Fibrates: therapeutic potential for diabetic nephropathy?
Topics: Animals; Creatinine; Diabetic Nephropathies; Disease Progression; Fenofibrate; Fibric Acids; Humans; | 2012 |
[Soluble VCAM-1].
Topics: Biomarkers; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; | 2002 |
3 trials available for fenofibrate and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia.
Topics: Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fenofibrate; Gl | 2020 |
Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Ty | 2018 |
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2005 |
27 other studies available for fenofibrate and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Dietary restriction and medical therapy drives PPARα-regulated improvements in early diabetic kidney disease in male rats.
Topics: Animals; Diabetes Mellitus; Diabetic Nephropathies; Fenofibrate; Kidney; Male; Niacinamide; PPAR alp | 2022 |
Fenofibrate Attenuates Renal Tubular Cell Apoptosis by Up-Regulating MCAD in Diabetic Kidney Disease.
Topics: Acyl-CoA Dehydrogenase; AMP-Activated Protein Kinases; Animals; Apoptosis; Diabetes Mellitus; Diabet | 2023 |
The Role of Akt2 in the Protective Effect of Fenofibrate against Diabetic Nephropathy.
Topics: Animals; Apoptosis; Blotting, Western; Diabetic Nephropathies; Fenofibrate; Fibroblast Growth Factor | 2020 |
Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy.
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; | 2018 |
Attenuated Lymphatic Proliferation Ameliorates Diabetic Nephropathy and High-Fat Diet-Induced Renal Lipotoxicity.
Topics: Acute Kidney Injury; AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Line; Cell Proliferatio | 2019 |
Altered expression profile of renal α(1D)-adrenergic receptor in diabetes and its modulation by PPAR agonists.
Topics: Animals; Cell Dedifferentiation; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Gen | 2014 |
Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1α in db/db mice.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; bcl-2-Associated X Protein; Diabetic Nephropathie | 2014 |
Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats.
Topics: Animals; Blood Glucose; Cholesterol; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropat | 2014 |
Renoprotective Effects of Fenofibrate via Modulation of LKB1/AMPK mRNA Expression and Endothelial Dysfunction in a Rat Model of Diabetic Nephropathy.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Blood Glucose; Diabeti | 2015 |
Up-regulation of Nrf2 is involved in FGF21-mediated fenofibrate protection against type 1 diabetic nephropathy.
Topics: Animals; Apoptosis; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetic Nephropathies; | 2016 |
Fenofibrate attenuates diabetic nephropathy in experimental diabetic rat's model via suppression of augmented TGF-β1/Smad3 signaling pathway.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fenofibrate; Gene Expression Regul | 2016 |
Delayed treatment with fenofibrate protects against high-fat diet-induced kidney injury in mice: the possible role of AMPK autophagy.
Topics: Albuminuria; AMP-Activated Protein Kinases; Animals; Autophagy; Diabetic Nephropathies; Diet, High-F | 2017 |
Interaction of PPARα With the Canonic Wnt Pathway in the Regulation of Renal Fibrosis.
Topics: Animals; beta Catenin; Blotting, Western; Cells, Cultured; Diabetic Nephropathies; Fenofibrate; Fibr | 2016 |
Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Chelating Agents; Diabetes Mellitu | 2009 |
Preventing diabetic complications: a primary care perspective.
Topics: Cost of Illness; Diabetes Complications; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neu | 2009 |
The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Creatinine; Diabetic Nephropathies; Disease Models, Ani | 2010 |
Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy.
Topics: Actins; Animals; Collagen; Diabetic Nephropathies; Fenofibrate; Fibrosis; Hypolipidemic Agents; Infl | 2010 |
Do fibrates truly preserve kidney function?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Humans; Kidney; Kidney Diseases | 2011 |
Diabetes: Should we use fibrates in patients with diabetes and mild CKD?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic | 2012 |
The combined strategy with PPARα agonism and AT₁ receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Creatine | 2012 |
Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy.
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Body Weight; Creatinine; Diabetic Nephropathies; Dose-R | 2013 |
Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha.
Topics: Animals; Blood Pressure; Collagen; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fatty Ac | 2006 |
[Effect of fenofibrate and metformin on lipotoxicity in OLETF rat kidney].
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Kidney; Lipid Metabolism; M | 2006 |
Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Extracellular Mat | 2006 |
The PPARalpha ligand fenofibrate: meeting multiple targets in diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Humans; Hypolipidemic Agent | 2006 |
PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.
Topics: Albuminuria; Animals; Blood Glucose; Body Weight; Cells, Cultured; Collagen Type I; Diabetes Mellitu | 2006 |
Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Fenofibrat | 2008 |